PI3K-AKT-mTOR通路对骨肉瘤细胞顺铂耐药性的影响及其机制

doi:10.3760/cma.j.cn101202-20200315-00082

摘要
图/表
参考文献(18)
相关文章 (10)

全文: PDF (1585 KB) HTML (2 KB)
输出: BibTeX | EndNote (RIS)

摘要目的探讨磷脂酰肌醇3-激酶(PI3K)-蛋白激酶B(AKT)-哺乳动物雷帕霉素靶蛋白(mTOR)通路对骨肉瘤细胞顺铂耐药性的影响及其机制,为骨肉瘤的靶向治疗提供新的思路。方法体外培养MG-63细胞,予2 μg/mL顺铂重复给药建立MG-63耐药细胞株,向MG-63耐药细胞株中转染miRNA-22高表达质粒建立miRNA-22高表达的MG-63耐药细胞株。以MG-63细胞为对照组,MG-63耐药细胞为耐药组,用2 μg/mL顺铂处理后的MG-63耐药细胞和转染miRNA-22的MG-63耐药细胞分别为耐药DDP组、耐药miRNA-22+DDP组。采用噻唑兰(MTT)法检测细胞增殖能力。采用荧光定量逆转录聚合酶链反应(RT-PCR)法检测细胞内PI3K、AKT以及mTOR mRNA的表达。采用Western blot检测细胞内PI3K、AKT以及mTOR蛋白的表达。结果 (1)MTT法检测结果显示,对照组、耐药组、耐药DDP组和耐药miRNA-22+DDP组的吸光度分别为1.097±0.039、1.157±0.065、0.870±0.014和0.737±0.029,差异有统计学意义(F=67.731,P＜0.01):与对照组比较,耐药DDP组、耐药miRNA-22+DDP组吸光度均明显下降,差异均有统计学意义(P值均＜0.01);耐药组、耐药DDP组、耐药miRNA-22+DDP组3组间比较,吸光度呈下降趋势,差异均有统计学意义(P值均＜0.01)。(2)荧光定量RT-PCR结果显示,与对照组比较,耐药组、耐药DDP组PI3K、AKT的相对表达量均增多,尤其以耐药组增多明显(P值均＜0.01),耐药miRNA-22+DDP组与对照组差异均无统计学意义(P值均＞0.01);而mTOR相对表达量耐药组增高,耐药DDP组、耐药miRNA-22+DDP组均降低,差异均有统计学意义(P值均＜0.01)。耐药DDP组、耐药miRNA-22+DDP组PI3K、AKT、mTOR的相对表达量均低于耐药组,差异均有统计学意义(P值均＜0.01);而耐药miRNA-22+DDP组仅PI3K、mTOR的相对表达量低于耐药DDP组,差异均有统计学意义(P值均＜0.01)。(3)Western blot检测结果显示,与对照组比较,耐药组PI3K、AKT、mTOR蛋白的相对表达量均明显增加,耐药DDP组、耐药miRNA-22+DDP组PI3K、AKT蛋白的相对表达量均明显降低,差异均有统计学意义(P值均＜0.01)。耐药组、耐药DDP组、耐药miRNA-22+DDP组3组间两两比较,耐药DDP组、耐药miRNA-22+DDP组PI3K、AKT、mTOR蛋白的相对表达量均明显低于耐药组,耐药miRNA-22+DDP组PI3K、AKT蛋白的相对表达量均明显低于耐药DDP组,差异均有统计学意义(P值均＜0.01)。结论 PI3K-AKT-mTOR通路参与了骨肉瘤细胞对顺铂耐药性的产生,miRNA-22通过下调PI3K-AKT-mTOR通路中PI3K、AKT以及mTOR的表达降低骨肉瘤细胞对顺铂的耐药性。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	娜日松
	郭世炳
	孙亮
	赵振群
	赵伟
	王玉鑫

关键词 ：骨肉瘤, 耐药性, 磷脂酰肌醇3-激酶-蛋白激酶B-哺乳动物雷帕霉素靶蛋白通路

Abstract：Objective This study aims to investigate the effect of the phosphatidylinositol 3-hydroxy kinase(PI3K)-protein kinase B(AKT)-mammalian target of rapamycin(mTOR) pathway on the drug resistance of osteosarcoma cells and its mechanism to provide new ideas for the targeted therapy of osteosarcoma.Methods MG-63 cells were cultured in vitro, and MG-63 drug-resistant cell lines were established using the repeated administration of 2 μg/mL cisplatin. The high-expression plasmids of miRNA-22 were transfected into MG-63 drug-resistant cell lines to establish MG-63 drug-resistant cell lines with high miRNA-22 expression. MG-63 cells were the control group, and the MG-63 drug-resistant cells were the drug-resistant group. MG-63 frug-resistant cells treated with 2 μg/mL cisplatin and the drug-resistant MG-63 cells transfected with miRNA-22 were the drug-resistant DDP and the drug-resistant miRNA-22+DDP groups, respectively. The cell proliferation was detected using the thiazoline (MTT) assay. The expression levels of PI3K, AKT, and mTOR mRNA were detected using fluorescence quantitative RT-PCR. The protein expressions of PI3K, AKT, pAKT, mTOR, and p-mTOR were detected using the Western blot.Results (1)The MTT results showed that the absorbance values of the control, drug-resistant, drug-resistant DDP, and drug-resistant miRNA-22+DDP groups were 1.097±0.039, 1.157±0.065, 0.870±0.014, and 0.737±0.029, respectively. The differences were statistically significant (F=67.731, P＜0.01). Compared with that of the control group, the absorbance of the drug-resistant DDP and the drug-resistant miRNA-22+DDP groups decreased significantly (all P values＜0.01). For the drug-resistant, drug-resistant DDP group, and drug-resistant miRNA-22+DDP group, the absorbance showed a downward trend, and the differences were statistically significant (all P values＜0.01). (2)The results of fluorescence quantitative RT-PCR showed that compared with that in the control group, the relative expression of PI3K and AKT in the drug-resistant and the drug-resistant DDP groups increased especially in the drug-resistant group (all P values＜0.01). No significant difference was observed between the drug-resistant miRNA-22+DDP and the control groups (all P values＞0.01). The relative expression of mTOR significantly increased in the drug-resistant group and significantly decreased in the drug-resistant DDP and the drug-resistant miRNA-22+DDP groups (all P values＜0.01). The relative expression levels of PI3K, AKT, and mTOR in the drug-resistant DDP and drug-resistant miRNA-22+DDP groups were lower than those in the drug-resistant group, and all differences were statistically significant (all P values＜0.01). The relative expression levels of PI3K and mTOR in the drug-resistant miRNA-22+DDP group were lower than those in the drug-resistant DDP group, and the differences were statistically significant (all P values＜0.01). (3) The results of Western blot showed that compared with that in the control group, the relative expression levels of PI3K, AKT, and mTOR proteins in the drug-resistant group increased significantly and that the relative expression levels of PI3K and AKT proteins in the drug-resistant DDP and drug-resistant miRNA-22+DDP groups were significantly reduced. The differences were statistically significant (all P values＜0.01). The pairwise comparison among three groups revealed that the relative expression levels of PI3K, AKT, and mTOR proteins in the drug-resistant DDP and drug-resistant miRNA-22+DDP groups were significantly lower than those in the drug-resistant group. The relative expression levels of PI3K and AKT proteins in the drug-resistant miRNA-22+DDP group were significantly lower than those in the drug-resistant DDP group (all P values＜0.01).Conclusions The PI3K-AKT-mTOR pathway was involved in the development of osteosarcoma cells' resistance to cisplatin. miRNA-22 reduced the resistance of osteosarcoma cells to cisplatin by downregulating the expression levels of PI3K, AKT, and mTOR in the PI3K-AKT-mTOR pathway.

Key words： Osteosarcoma Drug-resistance PI3K-AKT-mTOR pathway

收稿日期: 2020-03-15

基金资助:国家自然科学基金 (81660440);内蒙古自治区自然科学基金(2018MS08031)

通讯作者: 郭世炳,Email:guoshibing2017@sina.com

引用本文:

娜日松, 郭世炳, 孙亮, 赵振群, 赵伟, 王玉鑫. PI3K-AKT-mTOR通路对骨肉瘤细胞顺铂耐药性的影响及其机制[J]. 中华解剖与临床杂志, 2021, 26(1): 88-93.
Na Risong, Guo Shibing, Sun Liang, Zhao Zhenqun, Zhao Wei, Wang Yuxin. Effect of the PI3K-AKT-mTOR pathway on the drug resistance of osteosarcoma cells and its mechanism. Chinese Journal of Anatomy and Clinics, 2021, 26(1): 88-93.

链接本文:

http://www.cjac.com.cn/CN/10.3760/cma.j.cn101202-20200315-00082 或 http://www.cjac.com.cn/CN/Y2021/V26/I1/88

[1]	Nugent M. MicroRNA function and dysregulation in bone tumors: the evidence to date[J]. Cancer Manag Res, 2014, 6: 15-25. DOI:10.2147/CMAR.S53928.
[2]	孙亮, 郭世炳, 娜日松, 等. 微小RNA-22通过靶向调控异黏蛋白表达影响骨肉瘤细胞化疗敏感性[J]. 中华实验外科杂志, 2019, 36(11): 1959-1962. DOI:10.3760/cma.j.issn.1001-9030.2019.11.011.Sun L, Guo SB, Na RS, et al. MicroRNA-22 influenced on chemosensitivity of osteosarcoma cells by targeting metadherin[J]. Chin J Exp Surg, 2019, 36(11): 1959-1962. DOI:10.3760/cma.j.issn.1001-9030.2019.11.011.
[3]	赵家义. PI3K-AKT-mTOR信号通路抑制剂与肿瘤免疫治疗[J]. 中国肿瘤生物治疗杂志, 2017, 24(12): 1424-1430. DOI:10.3872/j.issn.1007-385x.2017.12.015.Zhao JY. Inhibitors of PI3K-AKT-mTOR signaling pathway and cancer immunotherapy[J]. Chin J Cancer Biother, 2017, 24(12): 1424-1430. DOI:10.3872/j.issn.1007-385x.2017.12.015.
[4]	Ma JF, Kalle MV , Plautz Q , et al. Relaxin promotes in vitro tumour growth, invasion and angiogenesis of human Saos-2 osteosarcoma cells by AKT/VEGF pathway[J]. European review for medical and pharmacological sciences, 2013, 17(10): 1345-1350.
[5]	陈晶, 李祎博, 邓金桂. 两种方法建立人宫颈癌细胞顺铂耐药细胞株及其耐药性的评价[J]. 中国民康医学, 2017, 29(13): 50-52, 62. DOI:10.3969/j.issn.1672-0369.2017.13.023.
[6]	Bousquet M, Noirot C, Accadbled F, et al. Whole-exome sequencing in osteosarcoma reveals important heterogeneity of genetic alterations[J]. Ann Oncol, 2016, 27(4): 738-744. DOI:10.1093/annonc/mdw009.
[7]	Yang JZ, Ma SR, Rong XL, et al. Characterization of multidrug-resistant osteosarcoma sublines and the molecular mechanisms of resistance[J]. Mol Med Rep, 2016, 14(4): 3269-3276. DOI:10.3892/mmr.2016.5590.
[8]	Chen R, Wang G, Zheng Y, et al. Drug resistance-related microRNAs in osteosarcoma: translating basic evidence into therapeutic strategies[J]. J Cell Mol Med, 2019, 23(4): 2280-2292. DOI:10.1111/jcmm.14064.
[9]	杨豪, 曹臣, 王力军. 长链非编码RNA LINC-PINT通过靶向miR-524-5p调控骨肉瘤细胞增殖凋亡的分子机制[J]. 中华肿瘤杂志, 2020, 42(4): 325-330. DOI:10.3760/cma.j.cn112152-20190726-00471.Yang H, Cao C, Wang LJ. LncRNA LINC-PINT regulating prolifetion and apoptosis of osteosarcoma cells by targeting miR-524-5p[J]. Chin J Oncol, 2020, 42(4): 325-330.DOI:10.3760/cma.j.cn112152-20190726-00471.
[10]	Wang L, Jiang J, Sun G, et al. Effects of lncRNA TUSC7 on the malignant biological behavior of osteosarcoma cells via regulation of miR-375[J]. Oncol Lett, 2020, 20(5): 133. DOI:10.3892/ol.2020.11994.
[11]	宋瑞鹏, 赵亮, 谭洪宇, 等. 磷酸肌醇3激酶/蛋白激酶B/哺乳动物雷帕霉素靶蛋白信号通路下p53基因对骨肉瘤细胞增殖及转移的抑制作用[J]. 中华实验外科杂志, 2018, 35(1): 26-28. DOI:10.3760/ema.j.issn.1001-9030.2018.01.010.Song RP, Zhao L, Tan HY, et al. Inhibitory effect of p53 on proliferation and metastasis of osteosarcoma via the phosphatidylinositol 3 kinase/protein kinase B/mammalian target of rapamycin pathway[J]. Chin J Exp Surg, 2018, 35(1): 26-28.DOI:10.3760/ema.j.issn.1001-9030.2018.01.010.
[12]	Duo J, Ma Y, Wang G, et al. Metformin synergistically enhances antitumor activity of histone deacetylase inhibitor trichostatin a against osteosarcoma cell line[J]. DNA Cell Biol, 2013, 32(4): 156-164. DOI:10.1089/dna.2012.1926.
[13]	刘春杰, 刘宇, 邓学坤, 等. miR-32通过调控PI3K/Akt信号通路影响骨肉瘤细胞的增殖[J]. 河北医科大学学报, 2018, 39(6): 662-667. DOI:10.3969/j.issn.1007-3205.2018.06.011.Liu CJ, Liu Y, Deng XK, et al. miR-32 affects proliferation of osteosarcoma cells by regulating PI3K/Akt signaling pathway[J]. Journal of Heibei Medical University, 2018, 39(6): 662-667. DOI:10.3969/j.issn.1007-3205.2018.06.011.
[14]	罗鸿斌, 刘蔚楠, 林建华, 等. mTOR抑制剂FIM-A对人骨肉瘤细胞株MG-63的抑制作用及其机制[J]. 中国肿瘤生物治疗杂志, 2013, 20(4): 419-424. DOI:10.3872/j.issn.1007-385X.2013.04.007.Luo HB, Liu WN, Lin JH, et al. Inhibitory effect of FIM-A, a mTOR inhibitor, on the proliferation and apoptosis of human MG-63 osteosarcoma cell line and its mechanism[J]. Chin J Cancer Biother, 2013, 20(4): 419-424. DOI:10.3872/j.issn.1007-385X.2013.04.007.
[15]	Zhang H, Jiang H, Zhang H, et al. Anti-tumor efficacy of phellamurin in osteosarcoma cells: Involvement of the PI3K/AKT/mTOR pathway[J]. Eur J Pharmacol, 2019, 858: 172477. DOI:10.1016/j.ejphar.2019.172477.
[16]	Ma H, Su R, Feng H, et al. Long noncoding RNA UCA1 promotes osteosarcoma metastasis through CREB1-mediated epithelial-mesenchymal transition and activating PI3K/AKT/mTOR pathway[J]. J Bone Oncol, 2019, 16: 100228. DOI: 10.1016/j.jbo.2019.100228.
[17]	Xu R, Liu S, Chen H, et al. MicroRNA-30a downregulation contributes to chemoresistance of osteosarcoma cells through activating Beclin-1-mediated autophagy[J]. Oncol Rep, 2016, 35(3): 1757-1763. DOI:10.3892/or.2015.4497.
[18]	Zhou X, Natino D, Zhai X, et al. MicroRNA-22 inhibits the proliferation and migration, and increases the cisplatin sensitivity, of osteosarcoma cells[J]. Mol Med Rep, 2018, 17(5): 7209-7217. DOI:10.3892/mmr.2018.8790.